230 related articles for article (PubMed ID: 31937834)
1. The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness.
Mus LM; Lambertz I; Claeys S; Kumps C; Van Loocke W; Van Neste C; Umapathy G; Vaapil M; Bartenhagen C; Laureys G; De Wever O; Bexell D; Fischer M; Hallberg B; Schulte J; De Wilde B; Durinck K; Denecker G; De Preter K; Speleman F
Sci Rep; 2020 Jan; 10(1):218. PubMed ID: 31937834
[TBL] [Abstract][Full Text] [Related]
2. Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis.
Lopez-Delisle L; Pierre-Eugène C; Louis-Brennetot C; Surdez D; Raynal V; Baulande S; Boeva V; Grossetête-Lalami S; Combaret V; Peuchmaur M; Delattre O; Janoueix-Lerosey I
Oncogene; 2018 Mar; 37(11):1417-1429. PubMed ID: 29321660
[TBL] [Abstract][Full Text] [Related]
3. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.
Cazes A; Lopez-Delisle L; Tsarovina K; Pierre-Eugène C; De Preter K; Peuchmaur M; Nicolas A; Provost C; Louis-Brennetot C; Daveau R; Kumps C; Cascone I; Schleiermacher G; Prignon A; Speleman F; Rohrer H; Delattre O; Janoueix-Lerosey I
Oncotarget; 2014 May; 5(9):2688-702. PubMed ID: 24811913
[TBL] [Abstract][Full Text] [Related]
4. ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.
Borenäs M; Umapathy G; Lai WY; Lind DE; Witek B; Guan J; Mendoza-Garcia P; Masudi T; Claeys A; Chuang TP; El Wakil A; Arefin B; Fransson S; Koster J; Johansson M; Gaarder J; Van den Eynden J; Hallberg B; Palmer RH
EMBO J; 2021 Feb; 40(3):e105784. PubMed ID: 33411331
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
6. Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.
Sattu K; Hochgräfe F; Wu J; Umapathy G; Schönherr C; Ruuth K; Chand D; Witek B; Fuchs J; Li PK; Hugosson F; Daly RJ; Palmer RH; Hallberg B
FEBS J; 2013 Nov; 280(21):5269-82. PubMed ID: 23889739
[TBL] [Abstract][Full Text] [Related]
7. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
8. Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.
Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA
Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566
[TBL] [Abstract][Full Text] [Related]
9. Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer.
Wulf AM; Moreno MM; Paka C; Rampasekova A; Liu KJ
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769149
[TBL] [Abstract][Full Text] [Related]
10. Targeting anaplastic lymphoma kinase (ALK) gene alterations in neuroblastoma by using alkylating pyrrole-imidazole polyamides.
Ota Y; Yoda H; Inoue T; Watanabe T; Shinozaki Y; Takatori A; Nagase H
PLoS One; 2021; 16(9):e0257718. PubMed ID: 34591871
[TBL] [Abstract][Full Text] [Related]
11. Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.
Van den Eynden J; Umapathy G; Ashouri A; Cervantes-Madrid D; Szydzik J; Ruuth K; Koster J; Larsson E; Guan J; Palmer RH; Hallberg B
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459281
[TBL] [Abstract][Full Text] [Related]
12. Nidogen 1 and Nuclear Protein 1: novel targets of ETV5 transcription factor involved in endometrial cancer invasion.
Pedrola N; Devis L; Llauradó M; Campoy I; Martinez-Garcia E; Garcia M; Muinelo-Romay L; Alonso-Alconada L; Abal M; Alameda F; Mancebo G; Carreras R; Castellví J; Cabrera S; Gil-Moreno A; Matias-Guiu X; Iovanna JL; Colas E; Reventós J; Ruiz A
Clin Exp Metastasis; 2015 Jun; 32(5):467-78. PubMed ID: 25924802
[TBL] [Abstract][Full Text] [Related]
13. RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma.
Eleveld TF; Schild L; Koster J; Zwijnenburg DA; Alles LK; Ebus ME; Volckmann R; Tijtgat GA; van Sluis P; Versteeg R; Molenaar JJ
Cancer Res; 2018 Nov; 78(21):6297-6307. PubMed ID: 30115695
[TBL] [Abstract][Full Text] [Related]
14. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
[TBL] [Abstract][Full Text] [Related]
15. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.
Pucci P; Lee LC; Han M; Matthews JD; Jahangiri L; Schlederer M; Manners E; Sorby-Adams A; Kaggie J; Trigg RM; Steel C; Hare L; James ER; Prokoph N; Ducray SP; Merkel O; Rifatbegovic F; Luo J; Taschner-Mandl S; Kenner L; Burke GAA; Turner SD
Nat Commun; 2024 Apr; 15(1):3422. PubMed ID: 38653965
[TBL] [Abstract][Full Text] [Related]
16. ALK Gene Copy Number Gain and Immunohistochemical Expression Status Using Three Antibodies in Neuroblastoma.
Kim EK; Kim S
Pediatr Dev Pathol; 2017; 20(2):133-141. PubMed ID: 28326957
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.
Lambertz I; Kumps C; Claeys S; Lindner S; Beckers A; Janssens E; Carter DR; Cazes A; Cheung BB; De Mariano M; De Bondt A; De Brouwer S; Delattre O; Gibbons J; Janoueix-Lerosey I; Laureys G; Liang C; Marchall GM; Porcu M; Takita J; Trujillo DC; Van Den Wyngaert I; Van Roy N; Van Goethem A; Van Maerken T; Zabrocki P; Cools J; Schulte JH; Vialard J; Speleman F; De Preter K
Clin Cancer Res; 2015 Jul; 21(14):3327-39. PubMed ID: 25805801
[TBL] [Abstract][Full Text] [Related]
18. Tumour-derived substrate-adherent cells promote neuroblastoma survival through secreted trophic factors.
Li J; Wang Y; Li L; Or PM; Wai Wong C; Liu T; Ho WLH; Chan AM
Mol Oncol; 2021 Aug; 15(8):2011-2025. PubMed ID: 33932101
[TBL] [Abstract][Full Text] [Related]
19. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma.
Umapathy G; El Wakil A; Witek B; Chesler L; Danielson L; Deng X; Gray NS; Johansson M; Kvarnbrink S; Ruuth K; Schönherr C; Palmer RH; Hallberg B
Sci Signal; 2014 Oct; 7(349):ra102. PubMed ID: 25351247
[TBL] [Abstract][Full Text] [Related]
20. The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells.
Puli OR; Danysh BP; McBeath E; Sinha DK; Hoang NM; Powell RT; Danysh HE; Cabanillas ME; Cote GJ; Hofmann MC
Neoplasia; 2018 Nov; 20(11):1121-1134. PubMed ID: 30265861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
